Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673217 · ClinicalTrials.gov registry record · Phase 1
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01673217 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT01673217, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of decitabine when given together with pegylated liposomal doxorubicin hydrochloride and vaccine therapy in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. Drugs used in chemotherapy, such as decitabine and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from a peptide or antigen may help the body build an effective immune response to kill tumor cells. Giving combination chemotherapy together with vaccine therapy may kill more tumor cells
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG decitabine
- BIOLOGICAL sargramostim
- BIOLOGICAL NY-ESO-1 peptide vaccine
- BIOLOGICAL incomplete Freund's adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673217
The ClinicalTrials.gov registry entry for NCT01673217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT01673217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673217 about?
NCT01673217 is a clinical study titled "Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer". This phase I trial is studying the side effects and best dose of decitabine when given together with pegylated liposomal doxorubicin hydrochloride and vaccine therapy in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. Drugs used in chemotherap...
What is the current status of trial NCT01673217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-04. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01673217?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), decitabine (DRUG), sargramostim (BIOLOGICAL), NY-ESO-1 peptide vaccine (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01673217?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.